July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Intraocular pressure lowering effect of the Hydrus Microstent implantation combined with cataract surgery in moderate to advanced glaucoma
Author Affiliations & Notes
  • Marta Toth
    Glaucoma Service, Moorfields Eye Hospital, London, United Kingdom
  • Gus Gazzard
    Glaucoma Service, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships   Marta Toth, None; Gus Gazzard, Alcon (R), Allergan (R), Ellex (R), Lumenis (R), Santen (R), Thea (R)
  • Footnotes
    Support  No
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2055. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marta Toth, Gus Gazzard; Intraocular pressure lowering effect of the Hydrus Microstent implantation combined with cataract surgery in moderate to advanced glaucoma
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):2055.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The Hydrus Microstent (Ivantis, Inc, Irvine, CA) is an innovative device designed to reduce intraocular pressure (IOP) by providing trabecular byass and Schlemm’s canal scaffolding. In our retrospective interventional case series we assessed the efficacy and safety of the Hydrus implantation combined with cataract operation.

Methods : We analyzed long-term follow up data of the patients who underwent cataract surgery combined with Hydrus implantation in our routine clinical practice. Outcomes included long term (8-12 months) changes of intraocular pressures and number of glaucoma medications, intraoperative complications and postoperative adverse events.

Results : Of 140 operated eyes 42 have one-year follow up data at the time of the abstract submission. Their average baseline visual field mean deviation was -11.2 ± 7.31 dB with a pattern standard deviation of 7.1 ± 3.77 dB. At baseline, 7% of them had 0 medication, 17% had 1 medication, 24% had 2 medications and 52% of them were on 3 or more medications to control their pressures. For all cases, mean preoperative IOP of 19.1 ± 5.1 mmHg decreased by 18% to 15.6 ± 4.6 mmHg by the end of the first year (p<0.001), and the mean medication count reduced from 2.4 to 1.5 (p<0.001). The proportion of patients with no medication has increased from 7% to 33% following Hydrus + cataract surgery. Out of the 42 operated eyes one had device-related postoperative complication of hyphema at week 1, which had resolved by the next visit.

Conclusions : The Hydrus Microstent combined with cataract surgery proves to be a safe procedure to achieve significant reduction in both intraocular pressure and medication intensity.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×